← Back to Search

Antiviral

Ganciclovir for Cytomegalovirus

N/A
Waitlist Available
Research Sponsored by National Center for Research Resources (NCRR)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients affiliated with Barnes-Jewish Hospital with CMV blood infection requiring antiviral therapy
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is looking at a new way to test how well the viral drug ganciclovir works to clear an infection of the CMV virus. This new test would let doctors know early on in the course of therapy whether or not the virus is responding to the drug, and if it is resistant to the drug.

Who is the study for?
This trial is for patients at Barnes-Jewish Hospital with a CMV blood infection who need antiviral treatment. Most participants are expected to be organ transplant recipients, but it's not mandatory. People can't join if they have very low white blood cell counts, poor kidney function, severe anemia, issues with drawing blood, live outside St. Louis during treatment or can't consent due to illness.Check my eligibility
What is being tested?
The study aims to develop a blood test that shows how fast the drug ganciclovir clears CMV infections in patients. It has two phases: Phase I involves detailed monitoring of the virus response in a few patients starting ganciclovir therapy; Phase II will use this data to optimize testing frequency and sample numbers.See study design
What are the potential side effects?
Potential side effects from ganciclovir may include problems related to bone marrow suppression such as low white blood cells (increasing infection risk), anemia (low red blood cell count causing fatigue), and impaired kidney function.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a patient at Barnes-Jewish Hospital and need antiviral treatment for my CMV infection.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

National Center for Research Resources (NCRR)Lead Sponsor
537 Previous Clinical Trials
317,016 Total Patients Enrolled

Media Library

Ganciclovir (Antiviral) Clinical Trial Eligibility Overview. Trial Name: NCT00004573 — N/A
Cytomegalovirus Research Study Groups:
Cytomegalovirus Clinical Trial 2023: Ganciclovir Highlights & Side Effects. Trial Name: NCT00004573 — N/A
Ganciclovir (Antiviral) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00004573 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are adults above twenty-five eligible to join this experiment?

"This medical experiment is open to participants above the age of majority and younger than 65 years old."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Kinetics of Response of Cytomegalovirus With Ganciclovir Treatment Using Quantitative Real-Time PCR
2024. "Kinetics of Response of Cytomegalovirus With Ganciclovir Treatment Using Quantitative Real-Time PCR". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00004573.
All > Cmv > Ic
~233 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top